Abstract The cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1
(VKORC1) genotypes have been strongly and consistently associated with warfarin dose …

Objective: To systematically review evidence on genetic variants influencing outcomes
during warfarin therapy and provide practice recommendations addressing the key …

Warfarin dosing algorithms adjust for race, assigning a fixed effect size to each predictor,
thereby attenuating the differential effect by race. Attenuation likely occurs in both race …

Objectives Recent clinical trial data cast doubt on the utility of genotype-guided warfarin
dosing, specifically showing worse dosing with a pharmacogenetic versus clinical dosing …

Introduction Cytochrome p450, family 2, subfamily F, polypeptide 2 (CYP4F2) catalyzes the
NADPH-dependent oxidation of the terminal carbon of long and very long chain fatty acids …

Background: The main aims of the present study were to develop a pharmacogenetic-based
warfarin dosing algorithm and to validate it in a highly admixed population. Materials & …

Aim: Extreme discordant phenotype and genome-wide association (GWA) approaches were
combined to explore the role of genetic variants on warfarin dose requirement in Brazilians …

BACKGROUND Warfarin is a widely prescribed anticoagulant, and its effect depends on
various patient factors including genotypes. Randomized controlled trials (RCTs) comparing …

Although the Hispanic population is continuously growing in the United States, they are
underrepresented in pharmacogenetic studies. This review addresses the need for …

Heart disease is a leading cause of death in the United States, and hypertension is a
predominant risk factor. Thus, effective blood pressure control is important to prevent …